These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 25035284)
1. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Hutzler JM; Cerny MA; Yang YS; Asher C; Wong D; Frederick K; Gilpin K Drug Metab Dispos; 2014 Oct; 42(10):1751-60. PubMed ID: 25035284 [TBL] [Abstract][Full Text] [Related]
2. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H Drug Metab Pharmacokinet; 2021 Dec; 41():100419. PubMed ID: 34624627 [TBL] [Abstract][Full Text] [Related]
3. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Hutzler JM; Yang YS; Albaugh D; Fullenwider CL; Schmenk J; Fisher MB Drug Metab Dispos; 2012 Feb; 40(2):267-75. PubMed ID: 22031625 [TBL] [Abstract][Full Text] [Related]
4. Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu Crouch RD; Blobaum AL; Felts AS; Conn PJ; Lindsley CW Drug Metab Dispos; 2017 Dec; 45(12):1245-1259. PubMed ID: 28939686 [TBL] [Abstract][Full Text] [Related]
5. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Akabane T; Tanaka K; Irie M; Terashita S; Teramura T Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103 [TBL] [Abstract][Full Text] [Related]
6. Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and In Vitro Methods. Jensen KG; Jacobsen AM; Bundgaard C; Nilausen DØ; Thale Z; Chandrasena G; Jørgensen M Drug Metab Dispos; 2017 Jan; 45(1):68-75. PubMed ID: 27737930 [TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
8. A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry. Crouch RD; Hutzler JM; Daniels JS Xenobiotica; 2018 Mar; 48(3):219-231. PubMed ID: 28281401 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401. Zhang JW; Deng HB; Zhang CY; Dai JQ; Li Q; Zheng QG; Wan HX; Yu HP; He F; Xu YC; Zhao S; Zhang JYJ Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):669-680. PubMed ID: 31030415 [TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Kamath AV; Wang J; Lee FY; Marathe PH Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625 [TBL] [Abstract][Full Text] [Related]
11. Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Klecker RW; Cysyk RL; Collins JM Bioorg Med Chem; 2006 Jan; 14(1):62-6. PubMed ID: 16143537 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Austin NE; Baldwin SJ; Cutler L; Deeks N; Kelly PJ; Nash M; Shardlow CE; Stemp G; Thewlis K; Ayrton A; Jeffrey P Xenobiotica; 2001; 31(8-9):677-86. PubMed ID: 11569533 [TBL] [Abstract][Full Text] [Related]
13. Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Sahi J; Khan KK; Black CB Drug Metab Lett; 2008 Aug; 2(3):176-83. PubMed ID: 19356090 [TBL] [Abstract][Full Text] [Related]
14. Refinement of In Vitro Methods for Identification of Aldehyde Oxidase Substrates Reveals Metabolites of Kinase Inhibitors. Dick RA Drug Metab Dispos; 2018 Jun; 46(6):846-859. PubMed ID: 29615437 [TBL] [Abstract][Full Text] [Related]
15. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Diamond S; Boer J; Maduskuie TP; Falahatpisheh N; Li Y; Yeleswaram S Drug Metab Dispos; 2010 Aug; 38(8):1277-85. PubMed ID: 20421447 [TBL] [Abstract][Full Text] [Related]
16. Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect. Zhang JW; Xiao W; Gao ZT; Yu ZT; Zhang JYJ Drug Metab Dispos; 2018 Dec; 46(12):1847-1855. PubMed ID: 30209037 [TBL] [Abstract][Full Text] [Related]
17. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Strelevitz TJ; Orozco CC; Obach RS Drug Metab Dispos; 2012 Jul; 40(7):1441-8. PubMed ID: 22522748 [TBL] [Abstract][Full Text] [Related]
18. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. Adusumalli S; Jamwal R; Obach RS; Ryder TF; Leggio L; Akhlaghi F Drug Metab Dispos; 2019 Aug; 47(8):874-882. PubMed ID: 31182423 [TBL] [Abstract][Full Text] [Related]
19. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans. Rodrigues AD; Ferrero JL; Amann MT; Rotert GA; Cepa SP; Surber BW; Machinist JM; Tich NR; Sullivan JP; Garvey DS Drug Metab Dispos; 1994; 22(5):788-98. PubMed ID: 7530622 [TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans. Xu L; Woodward C; Dai J; Prakash C Drug Metab Dispos; 2013 Dec; 41(12):2133-47. PubMed ID: 24046333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]